Magnetic nanoparticles in theranostic applications

Abstract

Nanomedicine research recently started exploring the combination of therapy and diagnostics, so-called theranostics, as an approach to offer a more flexible, personal, and precise care with improved patient outcomes. As magnetic nanoparticles show great potential in a variety of diagnostic and therapeutic applications, they are prime candidates to be used in a theranostic platform to realize this vision. This Perspective gives an overview of state-of-the-art magnetic imaging techniques and theranostic applications based on magnetic nanoparticles and discusses their opportunities and associated challenges. In order to address these challenges and to exploit these opportunities to the fullest, we discuss three promising research directions. The first considers the use of novel magnetic field sequences to utilize the rich magnetic dynamics of the particles, allowing a more accurate diagnosis and boosting the performance of many nanoparticle-based applications. Second, we introduce the innovative concept of smart theranostics based on feedback mechanisms between the particle applications and their supporting imaging procedure to enhance the performance of both and to allow real-time monitoring of treatment efficiency. Finally, we show the twofold advantage of applying data-driven models to enhance therapy and diagnostics on the one hand and for handling the platform’s large amount of data and associated decision support algorithms on the other. The latter research track is extended to include hybrid models in which physics-based and data-driven models are combined to overcome challenges of applications with limited data, making the data-driven part understandable, as well as in uncovering unknown nanoparticle dynamics. Contrasting other literature works, which mainly focus on developing magnetic nanoparticles with the right characteristics, we put forward advances in magnetic nanoparticle imaging techniques and applications to enable the use of a broader range of magnetic nanoparticles in theranostics. We seek to emphasize the importance of these building blocks as many research opportunities with a very high potential are still left open. Therefore, we encourage researchers to also take these aspects into account to advance theranostic applications of magnetic nanoparticles to real clinical environments.

Understanding the Effect of Magnetic Field and Nanoparticle Concentration on Brownian Relaxation Time in Magnetic Nanofluids: A Semi-Analytical Model

“…The obtained results, presented in this paper, are useful to understand the magnetic relaxation mechanisms with implications in various applications of the magnetic nanoparticle systems(Flores-Rojas et al 2022;Mittal et al 2022;Chen and Hou 2022;Coene and Leliaert 2022), especially for biomedical applications.…”

Insights into the Magnetic Properties of Single-Core and Multicore Magnetite and Manganese-Doped Magnetite Nanoparticles

“…Fe 3 O 4 nanoparticles are one of the most prepared and studied ferrite systems since they can be used in multiple different areas such as engineering applications, environmental technologies, and biomedicine. − Magnetite is one of the most attractive materials in the industrial field; apart from illustrating superparamagnetic behavior, it is nontoxic and easy to prepare with low-cost synthesis conditions. Also, it presents a microstructure dependent on different synthesis conditions such as temperature or doping, which makes the magnetite system a more versatile and application-rich material.…”

Heparin–Superparamagnetic Iron Oxide Nanoparticles for Theranostic Applications

“…Nowadays, contrast-enhanced magnetic resonance imaging (MRI) is one of the most effective methods of cancer and metastasis detection [ 2 ]. Superparamagnetic iron oxide nanoparticles (SPIONs) are the base of contrast agents such as Ferumoxide and Ferucarbotan, examples of commercialized formulations that are widely used as T2-weighted contrast agents (negative agent) and are rapidly replacing gadolinium-based contrast agents because of the risk of nephrogenic systemic fibrosis (NSF) [ 3 , 4 , 5 ].…”